Home
Welcome Note
Committees
Faculty
Timetable
Scientific Program
Poster Presentations
Poster Presentation Guidelines
Sponsorship & Exhibition
Sponsors & Exhibitors
Sponsorship Prospectus
Exhibition Floorplan
Exhibitor's Manual
Registration
Accommodation
CME
Tours
Accompanying Persons Tours
General Information
Before you travel ...
Webcasting
Wednesday, July 4, 2012
Thursday, July 5, 2012
About Tel-Aviv
About Israel
From Dan to Eilat
The People
Israeli Advanced Medicine
Partners
Contact Us
Friends of Israel
Urological Symposium

Tel Aviv Hilton, Tel-Aviv, Israel, July 3-5, 2012
  Scientific Program Print
Tuesday, July 3
      
18:30-20:00
Prostate Cancer Symposium
Supported by Ferring Canada & Ferring Israel
   
18:30-18:40
 
 
 
Welcome and Introduction
L. Klotz, Canada & J. Ramon, Israel
FOIU Congress co-chairpersons
        
18:40-19:00
The future of active surveillance
L. Klotz, Canada
   
19:00-19:20
GnRH antagonists vs. GnRH agonists: What is the difference?
J. Pinthus, Canada
    
19:20-20:00
Panel discussion: Practical management of patients on hormonal therapy
   
-When should Testosterone be measured?
-What is an adequate castration?
-Is intermittent hormonal therapy oncologically safe?
-Is there a place to revive the concept of neo-adjuvant hormonal therapy prior to surgery?
-Medical castration: At what intervals should depot be given?
    
Moderators: L. Klotz, Canada & J. Pinthus, Canada
Panel:
M. Cher, USA
N. Fleshner, Canada
M. Frydenberg, Australia
E. Rosenbaum, Israel
A. Sella, Israel
  
  
20:00
Get-Together
 

 

20:30
  
Guest Lecture
Aluf (Major General, res.) Amos Yadlin
"Israel's defense challenges"   
  
  
     
   
Wednesday, July 4
   
Session 1
Hall A
08:30-10:30
      
Prostate Cancer - 10-20 years from now
Chairpersons: L. Klotz, Canada & R. Reiter, USA
Based on my knowledge and experience, my educated guess is that in 10-20 years:
  
08:30-09:10
 
 
 
 
 
      
Screening and prevention
PSA will no longer be used for screening
Yes: E. Klein, USA
No: S. Loeb, USA
 
Prostate cancer prevention will be dead
Yes: M. Litwin, USA
No: N. Fleshner, Canada
               
09:10-09:20 5-Alpha reductase inhibitors will disappear due to concern about high-grade prostate cancer
R. Reiter, USA
  
09:20-09:35
The modified Gleason’s grading system will be re-modified and Gleason’s pattern 3 will no longer be considered “cancer”
J. Srigley, Canada
  
09:35-09:55
 
 
 
Active surveillance will be promoted to patients with Gleason’s 7 (3+4)
Yes: L. Klotz, Canada
No: M. Soloway, USA
          
09:55-10:05
Radical prostatectomy
Open radical prostatectomy will continue to be a common operation
M. Zerbib, France
   
10:05-10:15
Robotic radical prostatectomy will replace laparoscopic and open radical prostatectomy
C. Abbou, France
   
10:15-10:30
Focal and ablative treatment
Focal treatment will be widely accepted and utilized
A. Villers, France
     
Cryotherapy will be used for salvage only
A. Belldegrun, USA
    
HIFU will remain a “niche” treatment
Yes: J. Nelson, USA
No: I. Grunberger, USA
       
   
Session 2
Hall B
08:30-09:30
    
Pediatric Urology
Chairpersons: J. Kaneti, Israel & J. Elder, USA
08:30-08:45
  
      
Progress in hypospadias repair
W. Snodgrass, USA
         
08:45-09:00
Urologic malignancies in children: Long-term implications for adults
J. Elder, USA
   
09:00-09:30
Vesicoureteral reflux:
 
-Conflicting guidelines for treatment
-Endoscopic treatment
-Recurrent UTI's in females who had V-U reflux in childhood: Incidence, etiology and management
  
Moderator: J. Elder, USA
Panel
B. Chertin, Israel
P. Livne, Israel
Y. Mor, Israel  
W. Snodgrass, USA
   
 
Session 3
Hall B
09:30-10:30
   
Trauma and Reconstruction  
Chairperson: M. Coburn, USA & O. Shenfeld, Israel
09:30-09:50
 
         
 
Simulation as a cultural change vehilcle in emergency preparedness training and patient safety education
A. Ziv, Israel
The Israel Center for Medical Simulation (MSR)
         
09:50-10:30
Controversies in uretheral trama and reconstruction
  
Moderator: O. Shenfeld, Israel
Panel
J. Borin, USA
M. Coburn, USA
J. Elder, USA
R.P. Terlecki, USA
     
  
10:30-11:00
Coffee Break, Poster Viewing and Visit Exhibition
  
Session 4
Hall A
11:00-12:00
   
Guest Speakers
Chairperson: J. Ramon, Israel
11:00-11:30
 
 
  
   
  
        
Teva & Medicine - The covenant between Teva and our patients
Prof. Moshe Many
Vice-Chairman, Teva Pharmaceutical Industries Ltd, former president of Tel Aviv University
&
Dr. Jeremy Levin
President & CEO, Teva Pharmaceutical Industries, Ltd
      
11:30-12:00
Top disruption or Bottom disruption in the Medical Device industry
Kobi Richter
, PhD
Founder and chair of Medinol
   
  
  
  
Session 5
Hall A
12:00-13:00
  
OAB & Incontinence
Supported by Pfizer Israel
Chairpersons: G. Gillon, Israel & D. Staskin, USA
12:00-12:20
   
 
12:20-13:00
  
      
 
Is there a best anti-muscarinic drug?
J. Golomb, Israel
   
Managing the anti-muscarinic non-responders
    
Sacral neuro-stimulation
M. Guralnick, USA
Botox
D. Staskin, USA
Clam enterocystoplasty
H. Goldman, USA
  
  
Session 6
Hall B
12:00-13:00
  
Bladder Cancer
Chairpersons: A. Stein, Israel & M. Zerbib, France
12:00-12:10
  
    
Urothelial cancer biomarkers: Role in diagnosis and treatment decisions
S. Lerner, USA
        
12:10-12:20
  
  
 
12:20-13:00
High-grade T1 urothelial cancer of bladder
The role of pathology review of TURBT specimen
E. Oliva, USA
       
Case Discussion on high grade T1 tumor 
  
-Role of restaging
-BCG failure
-Primary cystectomy
-Novel treatments
   
Moderator: M. Soloway, USA
Panel
J. Baniel, Israel
S. Lerner, USA
A. Stein, Israel
M. Zerbib, France
  
        
13:00-14:00
Lunch Break
  
Session 7
Hall A
14:00-15:30
  
LUTS/BPH & Erectile Dysfunction: Links for casual relationship, management and treatment
Supported by Eli Lilly Israel
Chairpersons: S. Glina, Brazil & Y. Vardi, Israel
 
14:00-14:15
 
   
   
14:15-14:45
 
 
 
  
  
 
14:45-15:00
 
  
      
15:00-15:10
 
  
      
15:10-15:30
Pathogenic mechanisms linking BPH/LUTS and ED
S. Glina, Brazil
    
  
Impact of therapies for LUTS on ED
Medications
A. Greenstein, Israel
Surgery
E.F. Becher, Argentina
 
  
Impact of therapies for ED on LUTS
J. Chen, Israel
 
  
The rational for treating LUTS/BPH with PDE5-Is
Studies on the use of PDE5-Is for LUTS
Y. Vardi, Israel
  
Future directions
S. Glina, Brazil & Y. Vardi, Israel
 
 
Session 8
Hall B
14:00-15:30
  
Kidney Cancer
Chairpersons: O. Nativ, Israel & J. Nelson, USA
14:00-14:20
 
 
Highlights from the ISUP Consensus Conference on Adult Renal Tumor
B. Delahunt, New Zealand
        
14:20-14:40
  
   
14:40-15:00
   
 
15:00-15:30
Renal parenchimal preservation: How important is it?
O. Nativ, Israel
     
When should we suggest a radical nephrectomy?
M.-O. Timsit, France
     
Small renal mass
  
-Role of biopsy
-Role of surveillance
-Ablation
-Nephron-sparing surgery
-Role of robot surgery
-Role of TKI’s
   
Moderator: A. Zisman, Israel
Panel
A. Belldegrun, USA
G. Bratslavsky, USA
E. Klein, USA
O. Nativ, Israel
M.-O. Timsit, France
  
         
15:30-16:00
Coffee Break, Poster Viewing and Visit Exhibition
  
Session 9
Hall A
16:00-17:30
  
Advanced Kidney Cancer
Chairpersons: S. Lerner, USA & A. Sella, Israel
16:00-16:15
 
  
16:15-16:30
 
  
16:30-16:40
 
  
16:40-17:00
 
  
17:00-17:30
 
 

 

Management of IVC involvement
A. Saglowsky, USA
       
Kidney cancer surgery in the era of targeted cancer therapy
A. Belldegrun, USA
    
Update on neoadjuvant treatment 
A. Sella, Israel
    
The therapy of metastatic RCC
G. Bratslavsky, USA
          
Case Discussion
  
Moderator: S. Lerner, USA
Panel 
A. Belldegrun, USA
R. Berger, Israel
G. Bratslavsky, USA
A. Saglowsky, USA
A. Sella, Israel
A. Zisman, Israel
  
      
Session 10
Hall B
16:00-17:30
  
Robotic Surgery: Radical prostatectomy
Supported by Dover
Chairpersons: D. Kakiashvili, Israel & A. Shalhav, USA
 
 
16:00-16:15
   
 
 
    
16:15-17:30

Learning curve of robot-assisted laparoscopic radical prostatectomy
C. Abbou, France
A. Shalhav, USA
P. Stricker, Australia
    
Nerve-sparing radical prostatectomy: How I do it
  
Bladder neck dissection and dissection of seminal vesicles
C. Abbou, France
L. Goldenberg, Canada
D. Pushkar, Russia
P. Stricker, Australia
A. Tewari, USA
   
Nerve-sparing extirpation of the prostate
C. Abbou, France
L. Goldenberg, Canada
D. Pushkar, Russia
P. Stricker, Australia
A. Tewari, USA
       
Each speaker shall present his technique in a 5-minute video presentation for each topic
  
   
17:30-18:30
Moderated Poster Session
Chairpersons: E. Klein, USA & H. Winkler, Israel
    
17:30-17:36
  
  
Management of B.C.G. non-responders with fixed dose intravesical gemcitabine in superficial T.C.C. of urinary bladder
N. Mohanty, India
        
17:36-17:42
Pathology of bladder cancer among diabetic patients undergoing radical cystectomy with a history of pioglitazone (ACTOS) use
R.P. Terlecki, USA
   
17:42-17:48
Using micro-RNA expression to predict response to neo-adjuvant chemotherapy in urothelial carcinoma of the bladder - preliminary results and future plans
R. Leibowitz-Amit, Israel
   
17:48-17:54
A new microRNA-based diagnostic test for classification of kidney tumors
Z. Dotan, Israel
   
17:54-18:00
Prostate specific antigen/solvent interaction analysis (PSA/SIA): Continued examination of potential PSA isoforms for a new assay for prostate cancer
M. Stovsky, USA
  
18:00-18:06
A biopsy-based genomic approach to selecting men for active surveillance
E. Klein, USA
  
18:06-18:12
Hyperbaric oxygen therapy assessment in case of hemorrhagic cystitis after radiotherapy
W. Polom, Poland
  
18:12-18:18
Patient Perceived Outcomes after the AdVance male sling procedure for post-prostatectomy incontinence
E. Rijo, Spain
  
18:18-18:24
Influence of strict sperm morphology on the results of classic in vitro fertilization
S. Glina, Brazil
 
18:24-18:30
Cytokines in urine indicates urethral origin of urgency in the "overactive bladder syndrome"
O. Löfgren, Sweden
  
   
      
 
  
Thursday, July 5
   
Session 11
Hall A
08:30-10:30
    
ED/SD
Supported by Eli Lilly Israel
Chairpersons: A. Greenstein, Israel & J. Rajfer, USA
08:30-08:45
 
 
 Does sexual dysfunction and OAB / LUTS share a common physiological basis?
S. Glina, Brazil
        
08:45-09:00
Shockwave treatment for ED: Is there a potential for cure?
Y. Vardi, Israel  
     
09:00-10:00
Rehabilitation of sexual function after prostate cancer therapy:
Is there a difference in the management between radical prostatectomy and irradiation?
     
Moderator: J. Rajfer, USA
Panel
E.F. Becher, Argentina
J. Chen, Israel
S. Glina, Brazil
B. Kava, USA
     
10:00-10:15
Which treatment for ED patients with testosterone deficiency
E.F. Becher, Argentina
     
10:15-10:30
Discussion
     
  
Session 12
Hall B
08:30-09:30
    
Bladder Cancer
Chairpersons: D. Pode, Israel & M. Soloway, USA
08:30-09:00
  
   
Evolution of continent urinary diversion: Practical tips in construction and management
A. Sagalowsky, USA
         
09:00-09:15
Why we still divert the urine to conduits?
I. Leibovitch, Israel
  
09:15-10:30
Critical assessment of neo-adjuvant and adjuvant chemotherapy in muscle invasive urothelial carcinoma
     
Moderator: D. Pode, Israel
Panel
Z. Dotan, Israel
E. Gez, Israel
E. Klein, USA
S. Lerner, USA
M. Zerbib, France   
  
  
Session 13
Hall B
09:30-10:30
Male Urinary Incontinence
Chairpersons: J. Olsburgh, UK & S.V. Romano, Aregentina
09:30-09:40  
  
  
Incontinence following radiation therapy for prostate cancer
M. Wygoda, Israel
    
09:40-10:10
  
   
   
   
    
    
  
     
10:10-10:30
Post prostatectomy incontinence: Surgical options
  
Male sling
S.V. Romano, Argentina
ProAct balloons
I. Grunwald, Israel
Artificial urinary sphincter
S. Herschorn, Canada
 
Case discussion
  
Moderator: Y. Vardi, Israel
Panel
S. Herschorn, Canada
D. Pode, Israel
S.V. Romano, Argentina
M. Wygoda, Israel
  
  
10:30-11:00
Coffee Break, Poster Viewing and Visit Exhibition
  
Session 14
Hall A
11:00-12:00
   
Guest Speakers
Chairperson: J. Ramon, Israel
11:00-11:30
 
 
 
Limits of life expectancy?  Lessons from ribosome research
Prof. Ada Yonath

Weizman Institute of Science, recipient of the Nobel Prize in Chemistry, 2009
      
11:30-12:00
Israel's outlook on The Arab Spring
Prof. Itamar Rabinovich
Israel's former ambassador in Washington DC and former president of the Tel Aviv University
        
  
   
 
Session 15
Hall A
12:00-13:00
  
Prostate Cancer
Chairpersons: M. Wygoda, Israel & M. Zelevsky, USA
12:00-12:20
  
  
 
   
     
Radiation hormonal therapy for intermediate risk prostate cancer: Is the survival benefit outweighed by the side-effects?
Combination therapy
M. Zelevsky, USA
Radiation alone
Z. Symon, Israel 
     
12:20-13:00
Positive surgical margins in radical prostatectomy
   
Pathological issues
J. Srigley, Canada
Incidence
O. Yossepowitch, Israel
Oncological impact
M. Cher, USA
Role of MRI
A. Villers, France
Adjuvant therapy
M. Wygoda, Israel
Surveillance and salvage therapy
O. Yossepowitch, Israel
Is there a gold standard for post-prostatectomy irradiation? 
M. Zelevsky, Israel
    
           
Session 16
Hall B
12:00-13:00
  
Testicular Cancer
Chairpersons: E. Gez, Israel & J. Sheinfeld, USA
12:00-12:15
  
  
Any role for an adjuvant treatment in stage-1 seminoma?
R. Berger, Israel
   
12:15-12:30
Is there a role for primary RPLND for stage-1 nonseminoma?
J. Sheinfeld, USA
   
12:30-13:00
Testicular-sparing surgery
  
-When?
-In whom?
-Surgical aspects
-Role of frozen section
-Adjuvant treatment
  
Moderator: J. Sheinfeld, USA
Panel
J. Baniel, Israel
R. Berger, Israel
E. Gez, Israel
I. Leibovitch, Israel
E. Oliva, USA
A. Sella, Israel
  
  
13:00-14:00
Lunch Break
  
Session 17
Hall A
14:00-15:30
  
Robotic Surgery: Cystectomy and renal surgery
Supported by Dover
Chairpersons: C. Abbou, France & O. Gofrit, Israel 
 
14:00-14:45
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Robotic partial nephrectomy
  
-Tips & tricks for the beginning console surgeon
-Selective arterial clamping
-Suturing techniques for closure of the collecting system
-Closure and approximation of the renal parenchyma
-Single-port nephrectomy
-Review on results and complications
  
Moderator: C. Abbou, France
Panel
G. Amiel, USA
J. Borin, USA
A. Shalhav, USA
D. Zilberman, Israel
                 
14:45-15:30
Robotic radical cystectomy 
  
-Tips & tricks for nerve sparing cystecomty
-Lymphadenectomy: Modified vs. Extensive
-Intracorporeal vs. Extracorporeal urinary diversion
-Review on robotic-induced complications
-Reivew on oncological outcomes
  
Moderator: A. Shalhav, USA
Panel
C. Abbou, France
G. Amiel, USA
O. Gofrit, Israel
R. Reiter, USA
  
  
Session 18
Hall B
14:00-15:30
  
Pelvic Organ Prolapse and Incontinence
Chairpersons: J. Golomb, Israel & D. Pushkar, Russia
14:00-14:15
    
   
Female pelvic floor disorders: Recognizing the problem
S. Herschorn, Canada 
       
14:15-15:30
Pelvic organ prolapse
 
-Conservative management
-Operative management:
        Vaginal approach vs. Abdominal approach
        To sling or not to sling?
        Surgical tips and tricks
   
Moderator: H. Goldman, USA
Panel
J. Golomb, Israel
S. Herschorn, Canada
D. Pushkar, Russia
D. Staskin, USA
  
  
15:30-16:00
Coffee Break, Poster Viewing and Visit Exhibition
  
Session 19
Hall A
16:00-17:30
  
Prostate Cancer: Castrate resistant
Chairpersons: A. Lindner, Israel & M. Litwin, USA
16:00-16:20
  
  
16:20-16:40
  
  
Overview of new agents 
M. Cher, USA
  
Abiraterone and MDV3100 data
A. Belldegrun, USA
       
16:40-17:20
What are the most pressing questions for clinical trials?
  
Moderator: A. Lindner, Israel & A. Sella, Israel
Panel
E. Klein, USA
L. Klotz, Canada
M. Litwin, USA
J. Nelson, USA
J. Pinthus, Canada
A. Villers, France
  
17:20-17:30
Bone health, pain control and palliation in patients with bone metastasis  
E. Gez, Israel
  
  
Session 20
Hall B
16:00-17:30
  
Infertility
Chairpersons: D. Golovsky, Australia & L. Ross, USA
16:00-16:15
 
  
16:15-16:30
  
 
16:30-16:45
 
 
16:45-17:00
 
   
Male Reproduction as a Public Health Issue 
L. Ross, USA
  
Testosterone Replacement in the Infertile Male
G. Raviv, Israel
 
Preservation of Fertility in Cancer Patients
S. Silber, USA
  
Posthumous reproduction
I. Rosenblum, Israel 
      
17:00-17:30
"Why a Urologist" in the evaluation and treatment of the infertile couple
   
Moderator: D. Golovsky, Australia
Panel
E. Amar, France
S. Silber, USA
S. Glina, Brazil
 
  
    
 



info@comtecmed.com
www.comtecmed.com
Headquarters & Administration:
53 Rothschild Boulevard,
PO Box 68,
Tel Aviv, 6100001, Israel
Tel: +972-3-5666166
Fax: +972-3-5666177 Email: Info@comtecmed.com
Comtec Spain:
Bailen, 95 - 97,
pral.1.a - 08009
Barcelona, Spain
Tel: +34-932081145
Fax: +34-934579291
Email: spain@comtecmed.com
Comtec China:
Suite 405, Universal Center Building
175 Xiang Yang Road South,
Shanghai 200031, China
Tel: +86-21-54660460
Fax: +86-21-54660450
Email: china@comtecmed.com
 
 
Copyright © 2007 comtecmed.com. All rights reserved.   The website was last updated on 07/28/2014 Created by     WebStudio.co.il